Anil Potti, the former Duke cancer researcher who has now retracted or corrected 18 papers amidst investigations into his work, is now working at a Grand Forks, North Dakota, cancer center. The Grand Forks Herald reports that Potti has worked at the Cancer Center of North Dakota since May. His new boss, William Noyes, told … Continue reading Anil Potti resurfaces with job at North Dakota cancer center
One of the biggest stories so far out of the American Society of Clinical Oncology (ASCO) meeting that just ended in Chicago was that of T-DM1, which, according to Ivan’s Reuters colleagues, “extended the length of time breast cancer patients lived without their disease getting worse.” (The news was even the subject of an embargo … Continue reading Lead author of major breast cancer study announced at ASCO co-authored two corrected papers with Anil Potti
A partial retraction has joined the ten retractions and five corrections of Anil Potti’s papers, this one of a 2008 paper in Molecular Cancer Therapeutics. The move comes 14 months after the retraction of the Nature Medicine paper upon which much of the Molecular Cancer Therapeutics paper was based. Here’s the notice:
Anil Potti, the former Duke oncology researcher who has now retracted ten papers amid continuing investigations into his work, has been reprimanded by the Missouri medical board. The reprimand, which was first reported by DukeCheck, became effective on March 6. In it, the Missouri State Board of Registration for the Healing Arts noted that the … Continue reading Missouri medical board reprimands Anil Potti
Updated at 1:40 p.m. Eastern: When original posted, this item reported, correctly, that the South Carolina Board of Medical Examiners’ website listed Anil Potti’s license as “suspended.” However, that status has now been changed to “active,” along with “No disciplinary action taken by the Board. This certifies that the above licensee is in good standing.” We are … Continue reading Update: Potti’s South Carolina medical license now listed as active
Anil Potti, the former Duke oncologist who has now retracted ten papers, is no longer listed as a staff member at the oncology practice that hired him sometime last year. The development, first reported by Duke Check, follows a 60 Minutes segment last week focused on Potti and Duke. Duke Check also noted that a … Continue reading Updated: Anil Potti out at Coastal Cancer Center; practice blames Duke for glowing recommendations
Anil Potti and his colleagues have retracted another paper, “Characterizing the Clinical Relevance of an Embryonic Stem Cell Phenotype in Lung Adenocarcinoma,” originally published in the December 15, 2009, issue of Clinical Cancer Research. According to the notice:
A 60 Minutes segment Sunday on Anil Potti has drawn national attention to the case, so we thought this would be a good time to compile all of the retractions and corrections in one place. Duke has said that about a third of Potti’s 40-some-odd papers would be retracted, and another third would have “a … Continue reading The Anil Potti retraction record so far
Anil Potti can add two corrections to his less-and-less impressive publication record. The mega-corrections — part of what we are close to being ready to call a trend in errata notices — in the Journal of Clinical Oncology (JCO) are, however, quite impressive, each with at least a dozen points. One of the corrections, for … Continue reading Two mega-corrections for Anil Potti in the Journal of Clinical Oncology
Former Duke oncology researcher Anil Potti has retracted another paper, marking his ninth withdrawal. The notice in the Journal of Clinical Oncology (JCO) reads: “An Integrated Genomic-Based Approach to Individualized Treatment of Patients With Advanced-Stage Ovarian Cancer” by Holly K. Dressman, Andrew Berchuck, Gina Chan, Jun Zhai, Andrea Bild, Robyn Sayer, Janiel Cragun, Jennifer Clarke, … Continue reading Anil Potti and colleagues retract ninth paper, this one in JCO